What is ABclonal?
Founded in 2016, ABclonal is dedicated to advancing life science research by providing a comprehensive suite of high-quality biological reagents. Their product catalog includes essential items such as antibodies, proteins, and ELISA kits, catering to researchers worldwide. The company's focus on critical research tools positions it as a key player in supporting scientific discovery and development within the biotechnology and pharmaceutical industries. ABclonal's commitment to quality and service aims to accelerate research outcomes for its global clientele.
How much funding has ABclonal raised?
ABclonal has raised a total of $92.9M across 1 funding round:
Series C
$92.9M
Series C (2021): $92.9M with participation from Sigma Square Capital, LYFE Capital, Kinghall Ventures, Sequoia Capital China, and Lucion Capital
Key Investors in ABclonal
Sigma Square Capital
Sigma Square Capital, established in 2015, focuses on emerging areas including the Internet, consumer upgrades, and healthcare, leveraging in-depth research and first-hand information for its investments.
Sequoia Capital China
Sequoia Capital China is a prominent venture capital firm known for its long-term investment approach and active partnership with entrepreneurs, supporting companies across various stages of growth globally.
LYFE Capital
LYFE Capital is an investment firm that has participated in ABclonal's funding rounds, contributing to the company's growth in the life sciences sector.
What's next for ABclonal?
With the recent infusion of major strategic investment, ABclonal is poised for accelerated growth and enhanced market penetration. This substantial backing, contributing to its $92.9M in total financing, suggests a strong investor confidence in the company's business model and future prospects. The company is likely to leverage this capital to expand its research and development capabilities, broaden its product portfolio, and potentially scale its service offerings. Strategic partnerships and further market expansion are anticipated as ABclonal solidifies its position in the competitive life science research market.
See full ABclonal company page
